Anzeige
Mehr »
Donnerstag, 26.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41038 | ISIN: US09071M3043 | Ticker-Symbol: YP2
Lang & Schwarz
26.06.25 | 07:00
3,283 Euro
-100,00 % -3,283
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOLINERX LTD ADR Chart 1 Jahr
5-Tage-Chart
BIOLINERX LTD ADR 5-Tage-Chart
RealtimeGeldBriefZeit
3,1803,38507:00

Aktuelle News zur BIOLINERX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.06.Where BioLine Rx Stands With Analysts5
17.06.BioLineRx stock maintains buy rating at H.C. Wainwright on cancer data2
31.05.Why BioLineRx Ltd. (BLRX) Surged Last Week5
30.05.BioLineRx Stock Soars 46% On Positive Phase 2 Pancreatic Cancer Trial Data8
30.05.BioLineRx reports promising pancreatic cancer trial data18
30.05.BioLineRx Ltd: BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting153- 4 of 11 PDAC patients in the pilot phase remained progression free at over one year - Poster presentation on Saturday, May 31 st TEL AVIV, Israel, May 30, 2025...
► Artikel lesen
28.05.Jones Trading maintains Hold on BioLineRx stock amid royalty prospects4
BIOLINERX Aktie jetzt für 0€ handeln
28.05.Jones Trading behält Hold-Rating für BioLineRx-Aktie bei Lizenzgebührenaussichten bei2
28.05.H.C. Wainwright Maintains Buy Rating, $26 Target on BioLineRx Stock2
28.05.BioLineRx projects cash runway into H2 2026 while advancing PDAC pipeline and APHEXDA royalty growth2
27.05.BioLineRx GAAP EPS of $0.00 beats by $0.95, revenue of $0.26M misses by $1.22M3
27.05.BioLineRx Ltd.: BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update187- Reports continued progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare disease - - New data from pilot...
► Artikel lesen
26.05.A Look at BioLine Rx's Upcoming Earnings Report2
23.05.BioLineRx Ltd. - 6-K, Report of foreign issuer2
01.04.BioLineRx stock rating cut to Hold at Jones Trading5
01.04.H.C. Wainwright raises BioLineRx stock target to $265
31.03.BioLineRx GAAP EPS of -$0.01, revenue of $28.94M1
31.03.BioLineRx Ltd. - 6-K, Report of foreign issuer-
31.03.BioLineRx Ltd. - 20-F, Annual and transition report of foreign private issuers1
31.03.BioLineRx Ltd.: BioLineRx Reports 2024 Financial Results and Provides Corporate Update148- Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases - - Executed license...
► Artikel lesen
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1